TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10082778

Group type: EXPERIMENTAL
Intervention: High calcium diet (4.67 g/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal calcium diet (2.0 g/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High calcium diet (4.67 g/L) and Normal calcium diet (2.0 g/L)
Number of subjects: 0
Study: 7728405

Group type: EXPERIMENTAL
Intervention: Elemental diet (E028)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (23 patients)
Number of subjects: 24
Study: 1932650

Group type: EXPERIMENTAL
Intervention: Intraoperative blood recovery system (IBRS)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mediastinal drainage blood recovery system (MBRS) combined with IBRS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Homologous blood (HB)
Number of subjects: 66
Study: 7153190

Group type: EXPERIMENTAL
Intervention: Individualized contingency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group contingency based on group average
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group contingency based on designated low-achieving student
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group contingency based on randomly selected student
Number of subjects: 0
Study: 30840961

Group type: EXPERIMENTAL
Intervention: Intermittent-full-standard-dose tamsulosin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low-dose tamsulosin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Full-standard-dose tamsulosin (Control)
Number of subjects: 93
Study: 28627980

Group type: EXPERIMENTAL
Intervention: Multi-intervention group (specialist-based, lifestyle modification and pharmacological treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care group (GP-provided care)
Number of subjects: 120
Study: 26402011

Group type: EXPERIMENTAL
Intervention: ST101 (10, 60, or 120 mg QD)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: ST101 (120 mg QD)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 23528656

Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy (CVC)
Number of subjects: 110
Study: 21267543

Group type: EXPERIMENTAL
Intervention: Supervised physiotherapy intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unsupervised home-based rehabilitation
Number of subjects: 40
Study: 19553296

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg/d for infants aged 2 wk to 6 mo; 10 mg/d for infants aged >6 mo)
Number of subjects: 2052

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2052
Study: 16892419

Group type: EXPERIMENTAL
Intervention: Paroxetine (maximum 60 mg by week 7)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 70
Study: 15469648

Group type: EXPERIMENTAL
Intervention: A‐38 fermented milk
Number of subjects: 8

Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 8
Study: 11289332

Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide (1,600 microg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral methylprednisolone (1 mg/kg daily) plus medium-dose inhaled budesonide (800 microg daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose inhaled budesonide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral methylprednisolone plus medium-dose inhaled budesonide
Number of subjects: 60
Study: 9710866

Group type: EXPERIMENTAL
Intervention: Fatigue protocol at 30 degrees/s
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fatigue protocol at 150 degrees/s
Number of subjects: 20
Study: 8038614

Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test (RAST)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Proliferative responses of peripheral blood mononuclear cells (PBMCs) to ovalbumin
Number of subjects: 27
Study: 2647896

Group type: EXPERIMENTAL
Intervention: Controlled-release oral morphine sulfate (MSC) dosed at 8-, 10-, and 12-hour intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS) dosed every four hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prestudy analgesics
Number of subjects: 0
Study: 29260713

Group type: COMPARATOR
Intervention: bare metal stent implantation
Number of subjects: 1498

Group type: COMPARATOR
Intervention: everolimus-eluting stent implantation
Number of subjects: 1498
Study: 29055383

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) collagen microspheres
Number of subjects: 0
Study: 26177074

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrrolate (27.5/15.6 μg twice daily)
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Indacaterol (27.5 μg twice daily)
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Glycopyrrolate (15.6 μg twice daily)
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2038
Study: 23262997

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Chloroquine plus primaquine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study: 20233822

Group type: COMPARATOR
Intervention: 70.2 Gy of combined photon and proton radiation
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: 79.2 Gy of combined photon and proton radiation
Number of subjects: 393
Study: 19043376

Group type: EXPERIMENTAL
Intervention: Bone resorption and formation markers (CTX and OC)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of CTX and OC levels
Number of subjects: 320
Study: 16875154

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg daily for 12 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 12947128

Group type: EXPERIMENTAL
Intervention: 570 kcal carbohydrate rich supplement
Number of subjects: 85

Group type: COMPARATOR
Intervention: Non-nutritive placebo
Number of subjects: 85
Study: 10803445

Group type: EXPERIMENTAL
Intervention: Exercise-induced QTc interval changes (prolongation by > or = 20 ms) in Group 2 (7 patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise-induced QTc interval changes (prolongation by < 20 ms or shortening) in Group 1 (13 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 20
Study: 8668288

Group type: EXPERIMENTAL
Intervention: Piroxicam cinnamate 30 mg tablets (Sinartrol), 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Piroxicam cinnamate 20 mg tablets, 1 tablet twice daily for 2 days followed by 1 tablet daily for 13 days
Number of subjects: 60
Study: 2053016

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 to 220 mcg/kg, five single oral doses, one every six months)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (identical appearance to ivermectin)
Number of subjects: 83
Study: 7379443

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30772863

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) administered by paramedics
Number of subjects: 11

Group type: COMPARATOR
Intervention: Usual care (most commonly morphine)
Number of subjects: 11
Study: 28917070

Group type: EXPERIMENTAL
Intervention: Daily consumption of sweets
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Occasional consumption of sweets
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Weekly consumption of carbonated beverages
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Daily consumption of carbonated beverages
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Weekly consumption of energy drinks
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Daily consumption of energy drinks
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with age
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with carbonated beverages
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with energy drinks
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with high fat food
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Association of daily sweets consumption with BMI
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Association of carbonated beverages with energy drinks
Number of subjects: 725
Study: 25772954

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (direct calls every 15 days for 4 months)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 440

Group type: COMPARATOR
Intervention: Control group (no mobile phone contacts, examined in clinic)
Number of subjects: 440
Study: 23672442

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 150
Study: 21867490

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (MIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (leaflet only)
Number of subjects: 0
Study: 19033683

Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (t‐PA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18167250

Group type: EXPERIMENTAL
Intervention: ALA 600 mg/d in normal saline 250 ml given by intravenous drip infusion once a day for 14 days
Number of subjects: 95

Group type: COMPARATOR
Intervention: Radix salviae 20 ml by intravenous drip infusion once a day for 14 days
Number of subjects: 95
Study: 15156419

Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale)
Number of subjects: 538
Study: 11869322

Group type: COMPARATOR
Intervention: Handsewn esophagogastric anastomosis
Number of subjects: 5
Study: 9703298

Group type: EXPERIMENTAL
Intervention: 0.025 mg of estradiol daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 0.05 mg of estradiol daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 0.1 mg of estradiol daily
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 8020522

Group type: EXPERIMENTAL
Intervention: iomeprol 150 mgI/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: iopamidol 150 mgI/ml
Number of subjects: 40
Study: 2644144

Group type: EXPERIMENTAL
Intervention: Cyclosporin (7.5 mg.kg‐1.day‐1)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 947969

Group type: EXPERIMENTAL
Intervention: 5 mg terbutaline sulfate orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 10
Study: 31775014

Group type: EXPERIMENTAL
Intervention: Three-yogurt bundle consisting of favorite yogurt products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-yogurt bundle consisting of three different yogurt products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual discrimination task on food bundles
Number of subjects: 0
Study: 31701526

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention for substance misuse prevention
Number of subjects: 1488
Study: 27755433

Group type: COMPARATOR
Intervention: Postoperative 40 mg bromelain every 6 hours for 6 days (Group B)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection (Group C)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Preoperative 4 mg dexamethasone sodium phosphate as a submucosal injection plus postoperative 40 mg bromelain every 6 hours for 6 days (Group D)
Number of subjects: 84
Study: 24633493

Group type: EXPERIMENTAL
Intervention: Metformin (Glucophage(®) 500 mg) 1 tablet twice daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sitagliptin (Januvia(®) 100 mg) 1 tablet/day
Number of subjects: 40
Study: 24286509

Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg biweekly)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg monthly)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 21736768

Group type: EXPERIMENTAL
Intervention: Enriched virgin olive oil (EVOO) (961·17 mg/kg oil)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control virgin olive oil (VOO) (288·89 mg/kg oil)
Number of subjects: 13
Study: 19423079

Group type: EXPERIMENTAL
Intervention: Typhoid vaccination
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 16
Study: 17443133

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin 96 mg/day orally
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 14594866

Group type: EXPERIMENTAL
Intervention: 100 g of carbohydrates (CHO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Noncaloric placebo drink (Pla)
Number of subjects: 16
Study: 11439385

Group type: EXPERIMENTAL
Intervention: sALS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: chronic peripheral neuropathies
Number of subjects: 59

Group type: COMPARATOR
Intervention: control subjects
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: sALS and chronic peripheral neuropathies
Number of subjects: 59
Study: 9682661

Group type: EXPERIMENTAL
Intervention: Fat-rich second meal
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-fat second meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nothing by mouth
Number of subjects: 6
Study: 7904978

Group type: EXPERIMENTAL
Intervention: Clamp with somatostatin (250 micrograms/hr)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control clamp without somatostatin
Number of subjects: 12
Study: 2599691

Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Boiled water
Number of subjects: 86
Study: 766164

Group type: EXPERIMENTAL
Intervention: Voltaren (diclofenac sodium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 60
Study: 31087530

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) exercise for 6 months
Number of subjects: 25
Study: 30208251

Group type: EXPERIMENTAL
Intervention: Cross‐conjugated anthraquinone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta‐connected dihydroxyanthracene
Number of subjects: 0
Study: 26625709

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D-fortified snack bar (2000 mg/d Ca and 25 µg/d vitamin D) consumed 2 snack bars/d for 9 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo snack bar (without Ca/vitamin D) consumed 2 snack bars/d for 9 weeks
Number of subjects: 152
Study: 24166866

Group type: EXPERIMENTAL
Intervention: Vitamin D3 400 IU
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vitamin D3 800 IU
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1600 IU
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2400 IU
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 22431837

Group type: EXPERIMENTAL
Intervention: 800 IU/d of vitamin E (α‐tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α‐lipoic acid (E/C/ALA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 400 mg of coenzyme Q 3 times/d
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 19192127

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Age group <34 years
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Age group >=34 years
Number of subjects: 547

Group type: COMPARATOR
Intervention: All medication arms
Number of subjects: 547
Study: 17621652

Group type: EXPERIMENTAL
Intervention: Magnetic navigation system (MNS) guidewires
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard guidewire (SG) techniques
Number of subjects: 6
Study: 17469417

Group type: EXPERIMENTAL
Intervention: Self-expandable metal stents (SEMS)
Number of subjects: 0
Study: 11953630

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conservative rehabilitation
Number of subjects: 62
Study: 9829111

Group type: EXPERIMENTAL
Intervention: HUD with low cognitive demand
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HUD with medium cognitive demand
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HUD with high cognitive demand
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 24
Study: 7620956

Group type: EXPERIMENTAL
Intervention: Stretch ePTFE grafts
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard ePTFE grafts
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 2709180

Group type: EXPERIMENTAL
Intervention: Warm perineal pack
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cold perineal pack
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Warm sitz bath
Number of subjects: 90
Study: 1101606

Group type: EXPERIMENTAL
Intervention: Etidocaine 0.5% and 1%
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% and 0.5%
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Etidocaine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 11
Study: 31562796

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 29035703

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Repeated contact control
Number of subjects: 151
Study: 26253612

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 4910

Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 4910
Study: 23680176

Group type: EXPERIMENTAL
Intervention: SAMBA
Number of subjects: 60

Group type: COMPARATOR
Intervention: DC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study: 21530317

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 40 ppm
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (equivalent concentration of nitrogen)
Number of subjects: 150
Study: 18278696

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (ebm) implementation in oncology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer registries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled clinical trials
Number of subjects: 0
Study: 16497685

Group type: EXPERIMENTAL
Intervention: 8 mg perindopril
Number of subjects: 12218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study: 12867351

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Illicit drug use
Number of subjects: 190
Study: 10980912

Group type: EXPERIMENTAL
Intervention: Aggressive treatment of dyslipidemia using lovastatin
Number of subjects: 0
Study: 9285081

Group type: EXPERIMENTAL
Intervention: Darkness (complete darkness)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Light (control condition)
Number of subjects: 25
Study: 8256106

Group type: EXPERIMENTAL
Intervention: Lariam (mefloquine) 250 mg on alternate weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fansidar (sulfadoxine and pyrimethamine) one tablet weekly
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lariam (mefloquine)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lariam (mefloquine) metabolite
Number of subjects: 105

Group type: COMPARATOR
Intervention: Fansidar (sulfadoxine and pyrimethamine)
Number of subjects: 105
Study: 3551425

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gastroplasty
Number of subjects: 57
Study: 31898526

Group type: EXPERIMENTAL
Intervention: Hand-washing with soap at key times and weekly nail clipping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intestinal parasitic infections (IPIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anaemia
Number of subjects: 0
Study: 30009729

Group type: EXPERIMENTAL
Intervention: AACD‐CPR
Number of subjects: 69

Group type: COMPARATOR
Intervention: STD‐CPR
Number of subjects: 69
Study: 26701977

Group type: EXPERIMENTAL
Intervention: 1.25 mmol/L Ca (1.25 Ca), n=212
Number of subjects: 425

Group type: COMPARATOR
Intervention: 1.75 mmol/L Ca (1.75 Ca), n=213
Number of subjects: 425
Study: 25683256

Group type: EXPERIMENTAL
Intervention: Salsalate (3 g/day for 7 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24386861

Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation (CAD) therapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Standard intermittent androgen deprivation (IAD) therapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Modified intermittent androgen deprivation (IAD) therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Modified IAD
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard IAD
Number of subjects: 93
Study: 20358216

Group type: EXPERIMENTAL
Intervention: BoNTA 300 U
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 18821290

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (intramuscular injections of testosterone enanthate every three weeks for 12 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 48
Study: 15669894

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 55
Study: 12558678

Group type: EXPERIMENTAL
Intervention: Preoperative neoadjuvant therapy for early stage locally advanced breast cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative and coordinated clinical care across disciplines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incentives for multidisciplinary care
Number of subjects: 0
Study: 11090787

Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 0